El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

689220.pdf (2.78 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2018-05-31

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/152802

Poly(2-Ethyl-2-Oxazoline) as an alternative to poly(Vinylpyrrolidone) in solid dispersions for solubility and dissolution rate enhancement of drugs

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.xphs.2018.05.015

Resum

Poly(2-ethyl-2-oxazoline) (PEOX), a biocompatible polymer considered as pseudopolypeptide, was introduced as a potential alternative to the commonly used polymer, poly(vinylpyrrolidone) (PVP) for the preparation of solid dispersion with a poorly soluble drug. Glipizide (GPZ), a Biopharmaceutical Classification System class II model drug, was selected for solubility and dissolution rate study. GPZ-polymer solid dispersions and physical mixtures were characterized and investigated by X-ray diffractometry, differential scanning calorimetry, scanning electron microscopy, and FTIR spectroscopy. The impact of polymers on crystal nucleation kinetics was studied, and PEOX exhibited strong inhibitory effect compared with PVP. Solubility and dissolution behavior of the prepared solid dispersions and their physical blends were in vitro examined and evaluated. A significant enhancement in GPZ solubility was obtained with PEOX compared with the pure drug and solid dispersion with PVP. A big improvement in the intrinsic dissolution rate (45 times) and dissolved amount of GPZ (58 times) was achieved with PEOX in fasted state simulated intestinal fluid, against comparable enhancement observed with PEOX and PVP in phosphate buffer at pH 6.8. Lower molecular weight of PEOX-5K (5000 g/mol) was found to be superior to higher molecular weight PEOX-50K (50,000 g/mol) in the improvement of dissolution behavior. The findings of this study with GPZ as a model drug introduce lower molecular weight PEOX as a promising polymeric carrier toward better oral bioavailability of poorly soluble drugs.

Matèries

Solubilitat dels medicaments, Disseny de medicaments

Matèries (anglès)

Drug solubility, Drug design

Citació

Col·leccions

Articles publicats en revistes (Enginyeria Química i Química Analítica)

Citació

FAEL, Hanan, RÀFOLS LLACH, Clara, DEMIREL, A. levent. Poly(2-Ethyl-2-Oxazoline) as an alternative to poly(Vinylpyrrolidone) in solid dispersions for solubility and dissolution rate enhancement of drugs. _Journal of Pharmaceutical Sciences_. 2018. Vol. 107, núm. 9, pàgs. 2428-2438. [consulta: 6 de gener de 2026]. ISSN: 0022-3549. [Disponible a: https://hdl.handle.net/2445/152802]

Exportar metadades

JSON - METS

Compartir registre